Masimo (NASDAQ:MASI – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 3.440-3.600 for the period, compared to the consensus estimate of 3.520. The company issued revenue guidance of $2.0 billion-$2.2 billion, compared to the consensus revenue estimate of $2.1 billion.
Masimo Stock Down 0.5 %
NASDAQ MASI opened at $135.92 on Friday. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. Masimo has a 1-year low of $75.22 and a 1-year high of $198.00. The company has a 50 day moving average of $135.66 and a 200-day moving average of $114.20. The company has a market cap of $7.19 billion, a price-to-earnings ratio of 90.01 and a beta of 0.97.
Masimo (NASDAQ:MASI – Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The company had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. During the same period in the previous year, the business earned $1.32 earnings per share. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. On average, equities research analysts expect that Masimo will post 3.51 earnings per share for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Research Report on Masimo
Hedge Funds Weigh In On Masimo
Hedge funds and other institutional investors have recently bought and sold shares of the company. Caisse DE Depot ET Placement DU Quebec acquired a new position in Masimo in the first quarter valued at $37,000. Belpointe Asset Management LLC lifted its holdings in Masimo by 31.4% in the first quarter. Belpointe Asset Management LLC now owns 339 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 81 shares during the period. Castleview Partners LLC acquired a new position in shares of Masimo during the first quarter valued at about $69,000. UniSuper Management Pty Ltd acquired a new position in shares of Masimo during the second quarter valued at about $66,000. Finally, Lazard Asset Management LLC raised its holdings in shares of Masimo by 20.0% during the first quarter. Lazard Asset Management LLC now owns 485 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 81 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.
Masimo Company Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Further Reading
- Five stocks we like better than Masimo
- 3 Best Fintech Stocks for a Portfolio Boost
- Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Comprehensive PepsiCo Stock Analysis
- With Risk Tolerance, One Size Does Not Fit All
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.